Acetaminophen in Pregnancy May Affect Childhood Behavior
12 variables, mainly features of hyperactive or attentive behavior, tied to acetaminophen use
Obstetrics and Gynecology
Slynd, a Progestin-Only Contraceptive, Now Available
Exeltis USA announced the commercial launch of Slynd (drospirenone), which is indicated for use by females of reproductive potential to prevent pregnancy. Slynd is a progestin-only contraceptive that lowers the risk of becoming pregnant primarily by suppressing ovulation. It contains the synthetic progestin drospirenone in a 4mg dosage strength that is given in a 24/4…
The Weekly Dose Podcast: Episode 4
This week: Pimavanserin trial stopped early; Influenza vaccination updates; The unusual case of the label update that wasn’t; E-cigarettes and lung illness; and new proposals from the DEA to reduce opioid production but to increase marijuana production.
n-3 PUFAs Do Not Lower Risk for Early Preterm Delivery
Maternal supplementation with n-3 long-chain polyunsaturated fatty acids did not lower risk
Addyi Alcohol Warnings Have Not Been Revised, Says FDA
We have recently learned that at this time, the Food and Drug Administration (FDA) has NOT revised its warnings about the use of alcohol with Addyi nor has it changed the drug’s REMS, according to an FDA spokesperson.
Position Statement Clarifies Benefits of Testosterone Therapy for Women
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Adolescent Oral Contraceptive Use Tied to Later Depression Risk
Findings show long-term impact, regardless of current oral contraception use in adulthood
Type and Timing of Menopausal HRT Affect Risk for Breast Cancer
Some excess risk persists for >10 years after ceasing therapy; magnitude varies with duration of use
Vyleesi Now Available to Treat Hypoactive Sexual Desire Disorder
Vyleesi (bremelanotide injection; AMAG Pharmaceuticals) is now commercially available through specialty pharmacies, Avella and BioPlus.
Prenatal Exposure to OMT Does Not Worsen Neonatal Outcomes
Growth parameters similar to those for newborns of women with opioid use disorders during pregnancy
